Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 10

1.

Myeloid derived suppressor cells (MDSCs) are increased and exert immunosuppressive activity together with polymorphonuclear leukocytes (PMNs) in chronic myeloid leukemia patients.

Giallongo C, Parrinello N, Tibullo D, La Cava P, Romano A, Chiarenza A, Barbagallo I, Palumbo GA, Stagno F, Vigneri P, Di Raimondo F.

PLoS One. 2014 Jul 11;9(7):e101848. doi: 10.1371/journal.pone.0101848. eCollection 2014.

PMID:
25014230
[PubMed - in process]
Free PMC Article
2.

SPARC expression in CML is associated to imatinib treatment and to inhibition of leukemia cell proliferation.

Giallongo C, La Cava P, Tibullo D, Barbagallo I, Parrinello N, Cupri A, Stagno F, Consoli C, Chiarenza A, Palumbo GA, Di Raimondo F.

BMC Cancer. 2013 Feb 5;13:60. doi: 10.1186/1471-2407-13-60.

PMID:
23383963
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Nuclear translocation of heme oxygenase-1 confers resistance to imatinib in chronic myeloid leukemia cells.

Tibullo D, Barbagallo I, Giallongo C, La Cava P, Parrinello N, Vanella L, Stagno F, Palumbo GA, Li Volti G, Di Raimondo F.

Curr Pharm Des. 2013;19(15):2765-70.

PMID:
23092325
[PubMed - indexed for MEDLINE]
4.

BRIT1/MCPH1 expression in chronic myeloid leukemia and its regulation of the G2/M checkpoint.

Giallongo C, Tibullo D, La Cava P, Branca A, Parrinello N, Spina P, Stagno F, Conticello C, Chiarenza A, Vigneri P, Palumbo GA, Di Raimondo F.

Acta Haematol. 2011;126(4):205-10. doi: 10.1159/000329911. Epub 2011 Sep 16. Erratum in: Acta Haematol. 2012;127(2):80. Acta Haematol. 2011;126(4):210.

PMID:
21934293
[PubMed - indexed for MEDLINE]
5.

Effects of second-generation tyrosine kinase inhibitors towards osteogenic differentiation of human mesenchymal cells of healthy donors.

Tibullo D, Barbagallo I, Giallongo C, La Cava P, Branca A, Conticello C, Stagno F, Chiarenza A, Palumbo GA, Di Raimondo F.

Hematol Oncol. 2012 Mar;30(1):27-33. doi: 10.1002/hon.988. Epub 2011 May 5.

PMID:
21544849
[PubMed - indexed for MEDLINE]
6.

Imatinib increases cytotoxicity of melphalan and their combination allows an efficient killing of chronic myeloid leukemia cells.

Giallongo C, La Cava P, Tibullo D, Parrinello N, Barbagallo I, Del Fabro V, Stagno F, Conticello C, Romano A, Chiarenza A, Palumbo GA, Di Raimondo F.

Eur J Haematol. 2011 Mar;86(3):216-25. doi: 10.1111/j.1600-0609.2010.01570.x. Epub 2011 Feb 8.

PMID:
21198861
[PubMed - indexed for MEDLINE]
7.

Overexpression of heme oxygenase-1 increases human osteoblast stem cell differentiation.

Barbagallo I, Vanella A, Peterson SJ, Kim DH, Tibullo D, Giallongo C, Vanella L, Parrinello N, Palumbo GA, Di Raimondo F, Abraham NG, Asprinio D.

J Bone Miner Metab. 2010 May;28(3):276-88. doi: 10.1007/s00774-009-0134-y. Epub 2009 Nov 19.

PMID:
19924377
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Concomitant and feasible treatment with dasatinib and the anti-EGFR antibody cetuximab plus radiotherapy in a CML patient with multiple squamous neoplasias.

Stagno F, Vigneri P, Del Fabro V, Stella S, Restuccia N, Giallongo C, Massimino M, Berretta S, Pennisi MS, Tibullo D, TirrĂ² E, Buscarino C, Messina A, Di Raimondo F.

Acta Oncol. 2010;49(1):109-10. doi: 10.3109/02841860903302913. No abstract available.

PMID:
19842797
[PubMed - indexed for MEDLINE]
9.

Effects of imatinib mesylate in osteoblastogenesis.

Tibullo D, Giallongo C, La Cava P, Berretta S, Stagno F, Chiarenza A, Conticello C, Palumbo GA, Di Raimondo F.

Exp Hematol. 2009 Apr;37(4):461-8. doi: 10.1016/j.exphem.2008.12.008.

PMID:
19302920
[PubMed - indexed for MEDLINE]
10.

A cytoprotective role for the heme oxygenase-1/CO pathway during neural differentiation of human mesenchymal stem cells.

Barbagallo I, Tibullo D, Di Rosa M, Giallongo C, Palumbo GA, Raciti G, Campisi A, Vanella A, Green CJ, Motterlini R.

J Neurosci Res. 2008 Jul;86(9):1927-35. doi: 10.1002/jnr.21660.

PMID:
18381758
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk